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1. Introduction 
Atrial fibrillation (AF) is the most common arrhythmia in adults and a major burden of 
morbidity and mortality in cardiovascular patients (1). The major sequelae are 
cardiovascular and include heart failure and thromboembolic events, primarily stroke. The 
prevalence of AF is 0.4-1% in the overall population which rises with age to approximately 
15% in those patients 70 years and older (2).  The incidence of AF is rising due in part to the 
increase in the aging population, increase in those living with structural cardiovascular 
pathology and more frequent diagnosis from the use of ambulatory monitoring devices.  
Overall, AF affects more than 2.5 million adult in the US and 200,000 to 250,000 in Canada 
(Heart and Stroke Foundation of Canada statistics; http://www.heartandstroke.com).  
Overall, this represents a considerable burden of illness in vulnerable populations such as 
the elderly and those with congestive heart failure.   
The Framingham Study found that development of chronic AF was associated with a two-
fold increase in mortality from cardiovascular disease (2). Furthermore, AF was an 
independent risk factor for mortality in this population (3). The risk of stroke with 
persistent AF is 8% per year and 2% per year with warfarin. This is balanced with a 
bleeding risk of 2% per year while on warfarin at an INR of 2-3 (4). Of 5070 patients in the 
Framingham Study followed for 34 years, a two-fold increase in stroke events were found 
with AF with higher rates in those with heart failure (5). The attributable risk of stroke 
increases with age from 1.5% for the youngest cohort (50-59 years) to 23.5% for the oldest 
cohort (80-89 years). 
AF is defined based on the clinical presentation, relevant patient characteristics and any 
associated cardiac pathology. There is considerable variation in the descriptors for types of 
atrial fibrillation. These include acute, chronic, long-standing, sustained, recurrent, and so 
forth. The Society of Thoracic Surgeons (STS) has published reporting guidelines to facilitate 
consistency in reporting which include classification of AF as paroxysmal, persistent and 
permanent; duration of arrhythmia and patient burden (percentage of overall time in AF) as 
well as previous interventions and relevant patient characteristics such as association with 
cardiac pathology (6). The European Society of Cardiology differs in that for AF lasting 
greater than 1 year, patients undergoing a rhythm control strategy have longstanding 
persistent AF whereas patients who have accepted the arrhythmia and are not therefore 
treated with rhythm control therapy have permanent AF. Table 1 provides the descriptors 
and definitions of AF utilized in this chapter. 
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AF Subtypes Definition 
Paroxysmal* >2 episodes, duration < 7 days, spontaneous termination 
Persistent* > 7 days or requires cardioversion 
Longstanding  Persistent >1 year with rhythm control treatment; failed or no  
cardioversion 
Permanent > 1 year without rhythm control treatment 
Primary / Lone Not associated with cardiac pathology, usually MR 
Secondary / Concomitant Associated with cardiac pathology 
Post-Operative Post-cardiac surgery, usually transient 
MR, mitral regurgitation 
* Characterized by the most frequent presentation  
Table 1. Definition of AF Subtypes 
Electrophysiologically, AF is characterized by irregular and uncoordinated atrial activation 
caused by macro re-entry circuits in left and right atria.  In paroxysmal AF, 90% of micro re-
entry circuits or triggers exist in close proximity to the pulmonary veins (in the context of 
mildly dilated atria) which trigger large macro-reentrant circuits (7). This is the basis for 
pulmonary vein isolation (PVI).  There is however evidence for extrapulmonary vein sites 
for initiation of AF which include superior vena cava (8), ligament of Marshall (9), left atrial 
(LA) posterior wall (10,11), coronary sinus, crista terminalis, interatrial septum, and LA 
appendage (LAA) (12). An important caveat is that most mapping studies have been 
performed in lone AF cases and may not be reflective of concomitant AF, particularly in 
atria with significant structural alterations. Atrial fibrillation may be conceptualized as a 
spectrum of severity. Paroxysmal AF resulting from macro reentry circuits in the absence of 
major tissue remodeling. If untreated, this may progress to persistent and then permanent 
AF with substrate alterations associated with atrial structural remodeling (Figure 1).  These 
later stages of AF may not be sufficiently addressed with PVI and may require a more 
extensive procedure, to be discussed in later sections.   
Patients with concomitant AF may have associated mitral pathology and possibly other 
valvulopathy as well as coronary disease. This is relevant as the atrial tissue is rendered 
susceptible to AF secondary to atrial stretch or damage, resulting in loss of myocardium and 
replacement fibrosis (13). The ultimate end result is electrical remodeling and shortened 
refractory periods (14).  In fact, left atrial size may be utilized as a surrogate marker for atrial 
remodeling. There also exists some evidence for a role of proinflammatory signaling as seen 
with active valvular or coronary disease and/or dysfunction of sinoatrial and 
atrioventricular nodes in AF development (15). 
Medical management of AF is based on rate or rhythm control as well as anticoagulation for 
stroke prevention. The Atrial Fibrillation Follow-up Investigation of Rhythm Management 
(AFFIRM) trial, a 4060 patient multicentered randomized controlled trial demonstrated no 
survival difference between rate and rhythm control at 3.5 years, although rate control was 
associated with fewer adverse events (16). Anticoagulation has been traditionally 
accomplished with warfarin (INR 2-3) for stroke prophylaxis but is associated with bleeding 
events. More recently, anticoagulation with the direct thrombin inhibitor dabigatran has 
shown similar stroke prevention rates with lower bleeding events and without the need for 
INR monitoring (17). 
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Fig. 1. Pathophysiology and surgical management of concomitant AF.  Atrial fibrillation 
may be described clinically as paroxysmal, persistent or permanent, which is associated 
with macro reentry circuits plus progressive left atrial remodeling.  Surgical management of 
paroxysmal AF may be limited to pulmonary vein isolation, but more chronic AF types 
require left-only or complete Maze IV lesion sets.  
Another rhythm control strategy is interventional. Generally patients with lone AF who are 
refractory to medical management are initially considered for catheter ablation. This is best 
suited for patients with paroxysmal AF where pulmonary vein isolation (PVI) alone may 
address the ectopic foci.  In patients with longstanding persistent or permanent AF, due to 
atrial substrate alterations, linear and ECG-guided extra pulmonary vein ablation may be 
necessary but even with these adjuncts, the success of less likely. The major limitation of this 
technology is inconsistent outcomes due to procedural failure and AF recurrence. For 
patients with paroxysmal AF, success is approximately 66% after a single procedure (18).  
Percutaneous LAA closure is also possible as an adjunct to ablation. 
Several devices have been developed and tested for percutaneous LAA closure for 
thromboembolic prevention. In the prospective, randomized controlled trial PROTECT-AF, 
the WATCHMAN LAA closure device (Atritech, Plymouth, MN) was found to be non-
inferior to warfarin alone for the composite endpoint of stroke, cardiovascular death, and 
systemic embolism (3.0 vs. 4.9/100 patient years) but hemorrhagic stroke was lower in the 
intervention group (19). There were, however, risk of procedural complications including 
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pericardial effusions and stroke, likely due to air embolism, and less commonly device 
embolization. Other devices used for percutaneous LAA closure include the PLAATO 
(Percutaneous LAA Transcatheter Occlusion) membrane-covered self-expandable nitinol 
cage system and the Amplatzer Septal Occluder (20,21). 
2. Surgical management of atrial fibrillation 
The underlying basis for surgical management of atrial fibrillation is targeted synthesis of scar 
tissue which does not conduct electrical impulses. We will consider surgical management of 
patients with primary or lone AF and those with concomitant valvular or coronary disease 
who are undergoing surgery and are being considered for adjunctive AF surgery.   
Of patients with lone AF, those that failed one or more attempts at catheter ablation or those 
who prefer surgery based on superior published outcomes, are considered for surgical 
management. Lee et al (22) reviewed AF surgery and correctly identified that patients with 
lone AF are generally unwilling to undergo sternotomy to address AF alone. In such 
patients, a minimally-invasive approach to AF surgery offers a reasonable alternative. These 
approaches include PVI, minimally-invasive Cox-Maze IV procedure or beating heart 
epicardial ablation, all through a right thoracotomy. 
More commonly, approximately half of patients with mitral valve disease have reported 
some degree of AF (23). The presence of AF increases mortality post-MV surgery. The cut-
and-sew maze, also known as the Cox-maze III procedure, has been the gold standard AF 
surgical technique for sinus restoration (24). However, due to the morbidity of cut-and-sew 
atrial lesions including those related to bleeding and increased CPB and cross-clamp times, 
most centers opt for the use of alternative energy sources. For paroxysmal AF without 
significant atrial enlargement, PVI alone may be a reasonable adjunctive procedure. For 
patients with persistent or permanent AF, the full Maze IV lesion set offers highest chance of 
success at sinus restoration. Although other modified lesions sets such as the Cox Mini-
Maze and left only-Maze procedure and others have been introduced, we will limit our 
discussion to the full Maze lesion set (25-27).  
2.1 Surgical techniques 
Ultimately the success of sinus restoration is dependent on the type and duration of AF, 
patient-specific and anatomical factors, and the successful creation of a transmural lesion 
set. Furthermore, for adjunctive procedures, the added surgical morbidity and mortality 
related to increased time on CPB and increased complications must be taken into 
consideration. All patients considered for AF surgery should have a careful assessment of 
their symptoms as well as transthoracic echocardiography for comprehensive assessment of 
left and right atrial anatomy. 
2.1.1 Maze procedure 
In 1987, Dr. Cox introduced the maze procedure and subsequently reported outcomes on 
the first seven patients who were free of AF (28). However, the original maze procedure 
was complicated by an inability to generate tachycardic response during exercise, left 
atrial dysfunction as well as surgical complexity and resulting long bypass and cross 
clamp times (29). Since that time, the maze has undergone several iterations. As 
mentioned, the Cox Maze III is the gold standard for AF surgery. The Cox-maze III 
procedure is associated with a higher incidence of sinus restoration, improved sinus node 
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function, fewer pacemaker requirements and improved atrial function compared with its 
predecessors.  Importantly the Cox-Maze III has proven robust effectiveness in the setting 
of paroxysmal, persistent or permanent AF (30). Although this procedure has not been 
widely adopted, it is important to appreciate the lesion set which forms the basis of the 
Cox Maze IV procedure.   
The Cox Maze III procedure is generally performed as an adjunct to a mitral procedure. 
The left-sided lesion set is performed at the time of MV repair/replacement via the left 
atriotomy, then the right-sided lesion set is performed on the beating heart at the time of 
patient rewarming. Briefly, the complete lesion set for the Maze III may be performed as 
follows: The LA is entered via the inter-atrial groove. 1) PVI is performed to prevent the 
macro-reentry circuits originating from the PVs. To accomplish this, the left atriotomy is 
extended in a circumferential fashion, until all pulmonary veins are encircled and the left 
atrium completely detached from its base. 2) Then the LAA is isolated to block re-entry 
circuits at its base.  The LAA is excised and the remaining defect incorporated into the 
atriotomy closure. 3) The mitral line and coronary sinus (CS) lesion are created to block 
conduction originating from mitral orifice and the CS, respectively. The PV encircling 
incision is joined to the mitral annulus at its postero-medial aspect and the CS is spot 
cryoablated. 4) On the right side, the intercaval lesion circuits originate from the SVC and 
IVC. To block these circuits, the longitudinal atriotomy is fashioned along the free wall of 
the right atrium extending from the tricuspid annulus (atrioventricular groove) to the left 
atriotomy incision. 5) The right atrial counter lesion blocks signals originating from the 
RAA. A second incision is fashioned along the free wall of the RAA, once again 
originating at the level of the tricuspid annulus, however extending only partially along 
the wall of the atrium. The resulting island provides a conduction ‘corridor’ through 
which normal stimuli can travel. 6) The T-lesion blocks RA flutter waves and reentry 
circuits (31). The right atrial isthmus incision is created, once again, using cryoablation. 
In cases of concomitant and continuous AF with normal RA size and no evidence of flutter 
waves, as the source is likely the LA, some groups have suggested that a left-only Maze may 
be sufficient. This would avoid a more complex operation with incision into the RA.  
However, the RA isthmus has been identified as a source of atrial flutter. As such, atrial 
flutter post-left Maze may necessitate additional right atrial catheter ablation (32). If the RA 
dimension is abnormal, the RA may support two of more macro reentrant circuits and a full 
Maze lesion set is recommended. Furthermore, a full Maze lesion set is recommended in 
cases where atrial flutter is present or when the RA is already opened.   
In 2004, the Cox-maze IV was introduced which replaced most surgical incisions with 
alternative energy sources (33). This has significantly shortened cross-clamp times 
compared with the Cox-maze III (41min vs 93 min) with comparable short term freedom 
from AF (34). The lesion set of the Cox Maze IV is shown in Figure 2. On the left, the PVs 
are isolated and two linear ablation lines are used to create a box lesion. Voeller et al (35) 
found that a box lesion around all four PVs which completely isolates the posterior LA 
wall led to greater mid-term freedom from AF as opposed to isolation in pairs. The LAA 
is surgically removed but if performed through a right thoracotomy, the LAA is oversewn 
from the inside. The mitral line is created and the CS is cryoablated. On the right the 
intercaval lesion is created. Through the right atriotomy the counter lesion and T-lesion 
are created.   
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Fig. 2. Illustration of lesion sets for Cox-Maze IV and GP ablation.  We illustrate left and 
right Maze IV lesions (dotted lines) as well as foci for GP (black circles) ablation. 
There are several alternative energy sources for the Cox Maze IV at different stages of 
development and clinical evaluation (Table 2). The major problem with such devices is the 
challenge of reliably creating a transmural lesion due to loss of energy to circulating blood 
creating a ‘heat sink’. The most commonly utilized ablation devices today are based on 
bipolar radiofrequency (RF) which addresses this challenge by focusing energy only in 
tissues between the jaws of the device, thereby eliminating surrounding blood.  
Radiofrequency can be delivered dry or saline-irrigated, the later may be more likely to 
deliver a transmural lesion by cooling the surface thereby creating a lesion of greater depth, 
however esophageal injury is a risk (36). With the use of any alternative energy source, it is 
important to use some confirmatory technique to ensure establishment of exit block. 
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Energy Source Advantage Disadvantage 
High Intensity  
Frequency Ultrasound 
Focused lesion 
Minimal ‘heat sink’  
Fixed penetration depth 
Unipolar RF May be irrigated/non-irrigated Significant ‘heat sink’  
Bipolar RF Energy focused between clamps - 
Minimal ‘heat sink’ 
Costly 
Microwave*  Significant ‘heat sink’  
Inconsistent lesion 
Cryoablation Less damage to adjacent critical 
tissue 
Reusable probe 
Slower 
Questionable transmurality 
Laser*  Significant ‘heat sink’  
Inconsistent lesion 
*No longer in clinical use 
Table 2. Alternative Energy Devices for Maze IV 
2.1.2 Pulmonary vein isolation 
The identification of AF triggers adjacent to the PVs is the rationale for PVI (7). This can be 
performed successfully by a sternotomy, a thoracotomy or completely thoracoscopically. A 
minimally-invasive procedure via bilateral minithoracotomies for paroxysmal AF is 
associated with 80.8% freedom from AF at 1 year (37). Thoracoscopic bilateral PVI and LAA 
exclusion has also been described for treatment of lone AF refractory to cathether ablation 
(38,39). For patients with concomitant, paroxysmal AF, PVI may be performed using a 
bipolar RF device to create two lesions separately encircling left and right pulmonary veins 
for patients undergoing MV repair or replacement, AVR or CABG.   
2.1.3 Ganglion ablation 
Electrophysiological studies have found that ectopic impulses originating from the 
autonomic ganglionic plexus (GP) in epicardial fat adjacent to the atria-PV interface to be a 
source of arrhythmias (7, 40).  To address this, GP ablation may be performed as an adjunct 
to Maze procedure (Figure 2). A prospective randomized trial of 67 patients demonstrated 
improved freedom from AF with the addition of GP ablation to catheter-based PVI (85.3% 
vs 60.6% freedom from AF) at 4.3 months follow up (41). Similarly, comparison of patients 
of GP ablation with Maze vs. a case-matched control Maze cohort found significantly higher 
freedom from AF at 1 year (90% versus 50%)(42). 
2.1.4 Atrial plasty 
A subset of patients with AF is those with giant LA (GLA), defined as LA diameter > 65mm.  
This may occur as a primary defect in the LA wall or secondary to mitral valve pathology, 
Rheumatic or otherwise. Major complications of GLA include compression of 
bronchopulmonary and left ventricle, post-operative low output syndrome and respiratory 
complications.  Furthermore, LA enlargement exacerbates macro re-entrant circuits and is a 
risk factor for thromboembolic disease. Left atrial size was found to be a significant predictor 
for stroke and death in the Framingham Heart Study (43). Furthermore, GLA (70 vs 58mm, LA 
diameter) was associated with failure to restore sinus rhythm following Maze procedure at the 
time of MV surgery (44). Several studies have demonstrated that addition of left atrial plication 
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to mitral valve surgery improved restoration of sinus rhythm compared to mitral valve 
surgery alone (45, 46). However, others have shown greater than 50% recurrent arrhythmias in 
patients post-Cox Maze IV with LA size greater than 8cm even with a LA plasty (47).  
The surgical approaches for LA plasty include excision of either inferior or inferior and 
superior walls as well as the autotransplant approach. An added advantage of these 
techniques is excellent exposure of the mitral valve to facilitate replacement or repair. The 
classical wall plication targets the inferior LA wall and has since been modified to a para-
annular and superior approach (48). The biatrial reduction plasty when utilized with Maze IV 
during valvular surgery has demonstrated effective sinus restoration (49). In the combined 
superior-transseptal approach, the interatrial septum is opened at the fossa ovarium and 
extended to the inferior limbus and towards the LA appendage (50). The inferior wall can then 
be plicated from the LAA to the posteromedial aspect of the mitral valve using several 
interrupted sutures and reinforced with an over-and-over stitch. More recently, spiral 
resection has been proposed which extends a superior-transseptal left atriotomy in the 
direction of the left atrial appendage, to the inferior wall and then to the right atrial free wall 
(51). This approach is associated with an extensive suture line with increased bleeding risk but 
has the advantage of placation of the LA, RA and interatrial septum. Reef imbricate technique 
used as an adjunct to maze and MV surgery was associated with significant LA size reduction 
and sinus restoration in patients with LA enlargement and GLA, respectively (52). A ‘half-
moon’ continuous reef imbricate sutureline suture is placed between the left and right PVs and 
circumferentially around the left atriotomy.   
LA size reduction for GLA is associated with lower mitral valve surgical mortality, likely 
due to reduction in compression effects, low output syndrome, thromboembolic 
complications and restoration of sinus rhythm (48, 53). Whether reduction in LA size for 
patients with GLA undergoing mitral valve surgery in the absence of AF reduces the 
incidence of new onset AF is unknown. We generally do not perform reduction plasty in the 
absence of AF as LA size may undergo positive remodeling with relief of LA volume load.   
2.2 Adverse effects 
There has been no significant additive operative mortality with concomitant Maze 
procedures for patients undergoing coronary or valvular surgery (54). The reported risks of 
the Maze procedure include bleeding and blood transfusion, need for permanent pacemaker 
(PPM), impaired left atrial transport and rarely atrioesophageal fistula (54). Sinus node 
dysfunction immediately post-Maze is often reversible but if there is no recovery within 7-10 
days, PPM implantation should be considered. The overall incidence of sinus node 
dysfunction requiring PPM is approximately 3-4%. It is unlikely that Maze lesion sets cause 
direct harm to the sinoatrial node and more likely that successful ablation of AF uncovers a 
sick sinus requiring pacing (55). Importantly, atrial transport may become impaired as scar 
tissue does not contribute to atrial contractility and as portions of atrial tissue may still 
fibrillate, depending on the location of the lesion sets. 
2.3 Post-operative management 
All patients should be monitored by telemetry post-operatively for the duration of hospital 
admission. Also, all patients, regardless of freedom from AF immediate post-operatively, 
should continue on oral anticoagulation until comprehensive cardiology assessment at 3 and 
6 months time. It is not uncommon for patients to be in AF acutely post-operatively as atrial 
scar formation takes time to develop and thus success or failure of AF surgery should be 
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assessed at follow-up clinic 3-6 mo post-operatively. If patients are in sinus rhythm at this 
time, as assessed by the absence of symptoms, ECG or 24 hour Holter monitor, then oral 
anticoagulation is discontinued. All patients require routine cardiology follow-up to 
monitor for AF recurrence. 
3. Clinical evidence for surgical management of atrial fibrillation 
3.1 Sinus restoration 
Most evidence for the efficacy of Maze procedures are for concomitant AF during repair or 
replacement of mitral valve. Several observational studies strongly suggests that surgical 
intervention is beneficial for return to sinus rhythm (54,56,57).  The original Maze III cohort 
reported by Dr. Cox’s group showed 95.9% and 97.5% freedom from AF at 5.4 years 
performed in lone and concomitant AF, respectfully (54). In another report and perhaps 
more importantly, the stroke rate in this cohort was 0.1% per year over 11.5 years of follow-
up (56). As the authors mention, this is likely the result of 1) sinus restoration, 2) 
preservation of atrial transport function and 3) removal or obliteration of the LAA.  A single 
center trial comparing patients undergoing mitral valve replacement or repair demonstrated 
improved conversion to sinus rhythm with concurrent modified radiofrequency maze 
ablation versus medical treatment (75% vs 39%) at 1 year follow-up (57). Damiano et al (47) 
recently report 89% freedom success with the Maze IV at 1 year. This outcome is notable in 
that the results are comparable to those of the Maze III and they utilized a strict definition of 
success as freedom from AF, A flutter or atrial tachycardia as determined by ECG or 24h 
Holter monitor and disuse of arrhythmia medications. The predictors of late AF recurrence 
following with Maze IV were enlarged LA, failure to isolated the posterior LA and presence 
of early tachyarrhythmias (47). Other groups have recapitulated these results demonstrating 
similar conversions to sinus rhythm and lowered stroke rates.   
Six randomized controlled trials (RCTs) have been performed using various Maze 
procedures which have all demonstrated higher sinus restoration compared with no maze.  
The first RCT in 2001 randomized 30 patients with concomitant AF to demonstrate sinus 
restoration with saline-irrigated-cooled-tip-radiofrequency ablation (SICTRA) or MV 
surgery alone (58). In 2003, 35 patients who underwent either MV repair with Maze III or 
MV repair alone (2.5:1 ratio) at one year follow-up demonstrated 92% vs 20% freedom from 
AF (59). In another study, sixty-seven patients randomized to either adjuvant port-access 
irrigated radiofrequency Maze procedure demonstrated favorable freedom from AF at 1 
year (93.6% vs 9.4%)(60) compared with mitral rahe surgry alone. Another RCT 
demonstrated that PVI and Maze both demonstrated similar improvements in sinus 
restoration in patients with mitral valve disease compared with MV surgery alone (61).  Yet 
another RCT in 70 patients with Rheumatic heart disease demonstrated an improvement in 
sinus restoration (79.4% vs 26.9%) with SICTRA procedure (62). The largest trial included 
160 patients in India undergoing surgery for rheumatic valve disease with maze III, left 
maze, PV isolation or no AF surgery who experienced 62.5%, 57.5%, 67.5% and 20% return 
to sinus rhythm, respectively (63). Although these clinical trials are relatively small single 
center experiences with short-term follow up times, they demonstrate a consistent 
improvement in sinus rhythm restoration regardless of the underlying MV pathology and 
procedure used including maze III, Left Maze, Maze with alternative energy sources and 
PVI. Importantly, no clinical trial has yet demonstrated survival benefit with a Maze 
procedure. Clearly, a large multicenter RCT with long term follow up is necessary to 
conclusively demonstrate freedom from AF and survival benefit. Regarding survival 
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benefit, considering that medical therapy leading to sinus restoration has not demonstrated 
improved survival, it may not be surprising if surgery for AF does not show this (22). 
Two meta-analyses have been performed to date. The first is a meta-analysis of 69 studies, 
mostly retrospective, included 5885 patients with persistent, concomitant AF report that 
Maze III was associated with greater freedom from AF at 1-3 years and that biatrial Maze III 
was more effective than Left Maze III (92.0-87.1% vs 86.1-73.4% range over 1-3 years) (64).  
However, no significant differences were found in survival between surgical approaches 
compared to control groups. Forty-two percent of studies were small (<50 patients), only 
19% included control populations and most data was extrapolated from Kaplan-Meier plots.  
The authors made no attempt to screen studies but rather to perform a comprehensive 
examination of the current literature. Another meta-analysis of four RCT and six 
retrospective studies demonstrate weak evidence in support of a reduction in stroke but an 
increase in need for PPM following the Maze procedure (65).   
As mentioned, GLA is seen in a significant proportion of patients with AF. Several studies 
have demonstrated that addition of left atrial plication to mitral valve surgery improved 
restoration of sinus rhythm compared to mitral valve surgery alone (45, 46). Left atrial size 
reduction (69 to 55mm) was associated with a significant improvement in sinus restoration 
at 3 years compared with those that had mitral valve surgery and RF ablation alone (45).  
Furthermore, LA size reduction at the time of maze procedure improves outcomes. On the 
other hand, Choo et al (66) demonstrated similar sinus conversion rates comparing patients 
with GLA vs non-GLA (67.4 vs 61.1mm, LA diameter) undergoing mitral surgery and maze.  
Interestingly, another report from the same group found that patients under 50 had 
significantly better 5-year freedom from AF than those older than 50 (87.1% vs 77.3%, 
respectively) (67). These differences may be attributed, at least in part, to the somewhat 
arbitrary cut-off of GLA on the spectrum of LA enlargement. 
Compared with surgical outcomes, cathether-based ablation has inferior short term 
outcomes and longterm results are pending. Catheter-based RF ablation may be used for 
paroxysmal and persistent AF with overall mid-term rates of sinus restoration of 
approximately 50-80% (68-70).  More recently, Weerasooriya et al (71) present single center 
results demonstrating 5-year freedom from arrhythmia recurrence of 29% with one 
procedure and 63% with repeat ablation.  Consistent with these clinical outcomes, Niv et al 
(72) demonstrated that 95% of pulmonary veins tested post-catheter ablation at the time of 
subsequent Maze III/IV were not electrically-isolated. We recommend that catheter ablation 
be best suited for younger patients with new onset (<6 months) paroxysmal lone AF. This 
may be combined with percutaneous device closure of LAA which has proven non-inferior 
to anticoagulation for stroke prevention but as mentioned, initially associated with 
complications including pericardial effusion, bleeding and device embolization (73-75). 
There are several important considerations with respect to outcomes. When evaluating 
outcomes, it is important to clearly define the patient selection, choice of lesion set, energy 
source utilized and the use of a confirmatory technique for successful creation of a 
transmural lesion. Success or failure of AF surgery should be assessed following a blanking 
period of 3-6 months needed for scar tissue to develop. An important issue is the definition 
and measurement of procedural success. Early studies utilized mailed questionnaire or 
telephone interviews to determine if patients had symptoms or clinical events. A more 
accurate determination is ECG or 24-hour Holter monitor. More recently, the 
HRS/EHRA/ECAS consensus statement proposed a more stringent definition of success as 
the following: 1) freedom from AF, atrial fibrillation and atrial tachycardia lasting 
>30seconds and 2) off Vaughan-Williams class I and III anti-arrhythmic medications (76).  
Finally, much evidence has come from high-volume expert centers.  It is clear that patient 
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selection is key as is the surgical skill and knowledge of anatomy for comprehensive 
completion of a complete ablation set. It is unclear whether the outcomes in real-world 
practice at lower volume centers can mimic these results. 
3.2 Areas of uncertainty 
It is unclear whether patients with lone AF, should undergo percutaneous ablation or 
minimally invasive surgical ablation. As mentioned, the midterm outcome with catheter 
ablation is approximately 50-60% with repeat procedures. On the other hand, Weimar et al 
(77) demonstrated 90% freedom from AF and 84% freedom from AF off antiarrhythmic 
medication at 24 months. Even with video-assisted, thoracoscopic PVI and LAA exclusion 
procedure alone, Wang et al (2011) found improved freedom from AF compared to 
percutaneous ablation at 1-3.9 year follow up (74.7% vs. 59.0%). Yet another option which 
requires evaluation is off-pump, epicardial ablation for lone AF (78). Ultimately, the patient 
will have to balance the need for repeat intervention with catheter ablation vs. the upfront 
risk associated with surgery. 
It remains a challenge to identify those patient subsets for which AF surgery is unlikely to 
be beneficial. These include patients with paper thin LA, calcified walls, cardiothoracic ratio 
> 70% and a LA diameter > 80 mm (79). With regards to AF characteristics, low amplitude 
fibrillatory waves and longstanding AF (> 6 months) are associated with poor rates of sinus 
restoration. In addition, although the risk associated with the Maze procedure may be low, 
appropriate judgment must be exercised in selecting the most appropriate patients for this 
procedure. In very elderly or high risk patients, the potential benefits of a successful Maze 
procedure are unlikely to outweigh the risks of atriotomy and a longer bypass time. 
The importance of parasympathetic ganglion ablation to AF pathogenesis and whether such 
should be addressed is yet unclear. Ganglia plexi are located in epicardial fat pads in close 
proximity to the left and right PV antrum. The rationale for GP ablation is based on early 
basic studies which identified efferent parasympathetic and sympathetic processes in the 
GPs and implicated their involvement in triggering and sustaining AF (80,81). Ablation 
targets can be identified by vagal response to high-frequency stimulation. However, the 
additional benefit of adjunctive GP ablation to Maze procedure and the patient subset that is 
likely to benefit are not known. 
The optimal energy source for maze IV is yet unclear. Cryoablation has the advantage that it 
enables safe creation of the isthmus lesion as use of RF poses a risk of injury to vascular 
structures such as circumflex coronary artery. All unipolar devices including laser, 
microwave, unipolar RF and HIFU are limited as blood is not excluded from the interface 
thereby dissipating heat, thus negatively impacting transmurality, termed the ‘heat sink 
effect’ (82). Due to inconsistency in creation of transmural lesion sets, early energy sources 
such as microwave and laser have largely been discontinued.   
4. Guidelines 
In 2010, three major guideline revisions were released by the European Society of 
Cardiology (ESC)(83), by a joint committee of the American College of Cardiology 
Foundation (ACCF)/American Heart Association (AHA)/Heart Rhythm Society (HRS) and 
the Canadian Cardiovascular Society (CCS). Then in 2011, focused revisions were released 
by the American College of Cardiology Foundation (ACCF)/American Heart Association 
(AHA)/Heart Rhythm Society (HRS) in their respective journals (84). The CCS published 
their guidelines in 2011 and here we will focus on those that pertain to surgical management 
(85). 
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By in large, the recommendations of surgical management of atrial fibrillation are 
comparable. Bearing in mind that the data does not demonstrate a survival benefit for 
adjuvant ablation, the rationale for surgery include symptom relief, prevention of 
thromboembolism, preservation of atrial contraction and support of ventricular function in 
the setting of CHF. For symptomatic AF, the guidelines suggest a class IIa indication for 
adjuvant surgical ablation with two exceptions: the ACCF/AHA/HRS suggest a class I 
indication for paroxysmal AF and the CCS suggest a class I indication for AF with mitral 
valve disease. The ESC gives a class IIb and CCS suggest a conditional recommendation for 
surgical management of lone AF. 
The guidelines suggest that for patients with recurrent, paroxysmal AF who fail medical 
management, PV isolation or LA substrate modification may be considered. For patients 
with persistent AF with symptoms who fail or do not tolerate medical management, LA 
ablation, the maze and AV nodal ablation and pacing may be considered.  AF surgery is 
indicated for lone AF in patients who 1) prefer surgical management, 2) failed or have a 
contraindication to catheter ablation or 3) failed (developed thrombus) or have a 
contraindication to anticoagulation. 
5. Summary in points 
1. The gold standard surgical treatment for AF is the complete biatrial Cox-Maze lesion set 
2. The indications for atrial fibrillation surgery are the following: 
a. Recommendation for patients who i) prefer surgical management, ii) failed or have 
a contraindication to catheter ablation or iii) failed or have a contraindication to 
anticoagulation 
b. Recommendation for concomitant AF during a mitral valve procedure 
c. Conditional recommendation for lone AF 
3. Randomized controlled trials have consistently demonstrated that surgery for 
concomitant AF offer improved sinus restoration with very low additive risk. 
4. Atrial fibrillation surgery does not offer survival benefit. 
5. For lone AF, catheter ablation is currently the preferred technique but minimally-invasive 
Maze or PVI offers improved freedom from AF with a cosmetically-acceptable incision. 
6. Adjunctive procedures to a Maze are ganglia plexus ablation and left atrial plasty. The 
additive benefit of such still requires careful evaluation. 
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